You are here: Industry Insights > NMPA

News List

China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne prnasia
August 10, 2021
Ascletis Pharma Inc. announced that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne.
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial prnasia
August 10, 2021
ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration for clinical trial for treatments using intravenous administration ...
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval prnasia
August 05, 2021
China Pharma Holdings, Inc., a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to ...
CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA prnasia
August 03, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the China registrational study CS3010-101 of ...
Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Ch prnasia
July 09, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the National Medical ...
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002 prnasia
July 07, 2021
Transcenta Holding Limited announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.
CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy prnasia
July 07, 2021
CStone today announced that the investigational new drug (IND) application of CS2006/NM21-1480 has been accepted by the Center for Drug Evaluation, National Medical Products Administration (NMPA) of China.
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 prnasia
June 25, 2021
Lynk Pharmaceuticals Co., Ltd. announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD).
China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection prnasia
June 04, 2021
MicuRx Pharmaceutical Co., Ltd. announced that China National Medical Products Administration (NMPA) has approved its new drug application for contezolid as the treatment of complicated skin and soft tissue infection.
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication prnasia
May 27, 2021
Gannex today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for NASH indication.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page